Top Five Articles on 360Dx Last Week: OraSure Restructuring; DiaSorin Divestiture; and More
Last week, readers were most interested in OraSure's plans to combine its Molecular Solutions and Diagnostics businesses and eliminate some positions.
The firm now anticipates accelerating its commercialization phase by one to two years and will mix and match its technologies going forward.
Top Five Articles on 360Dx Last Week: Roche Mass Spec Plans, Jana Care Collaboration; and More
Last week, readers were most interested in Roche's planned launch of its mass spec clinical analyzer in a market that has proven challenging for other vendors.
Top Five Articles on 360Dx Last Week: Sherlock Bio's $2M Award; Nostics' POC Testing Plans; and More
Last week, readers were most interested in the Gates Foundation award to advance Sherlock Bio's CRISPR-based instrument-free molecular diagnostics platform.
Sherlock Biosciences Awarded $2M by Gates Foundation for Instrument-Free Diagnostics
The funding will be used to advance the firm's assay menu as well as to develop an integrated prototype diagnostic device.